Notably, CAR T cell immunotherapy targeting the pan-B-cell antigen CD19 has demonstrated significant success, particularly in achieving high remission rates among patients with ALL and non-Hodgkin lymphoma (NHL), leading to accelerated FDA approvals in 2017 [63,64]. This evidence concerns the gene CD19 and non-Hodgkin lymphoma.